OTHER INFORMATION
−Removed: the quarter ended March 31, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading
−Removed: arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation
+Added: During the quarter ended June 30, 2024,
+Added: no director or officer of the Company adopted
+Added: or terminated
+Added: a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in
+Added: Item 408(a) of Regulation S-K.
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
5 unchanged sentences
page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.*
+Added: __________________
* Filed herewith.
** Furnished herewith.
−Removed: to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
−Removed: the undersigned thereunto duly authorized, on May 20, 2024.
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934,
+Added: the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, on August 16, 2024.
SUNSHINE BIOPHARMA, INC.
Chief Executive Officer (principal executive officer)
+Added: /s/ Camille Sebaaly
Camille Sebaaly
−Removed: Financial Officer (principal financial and accounting officer)
+Added: Chief Financial Officer (principal financial and accounting officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.